|
Volumn 21, Issue 15, 2015, Pages 3372-3376
|
FDA approval summary: Ramucirumab for gastric cancer
|
Author keywords
[No Author keywords available]
|
Indexed keywords
PACLITAXEL;
PLACEBO;
RAMUCIRUMAB;
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
ABDOMINAL PAIN;
ANEMIA;
ARTERIAL THROMBOEMBOLISM;
ARTICLE;
ASCITES;
ASTHENIA;
BLEEDING;
DECREASED APPETITE;
DEHYDRATION;
DIARRHEA;
DIGESTIVE SYSTEM PERFORATION;
DISEASE COURSE;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG SAFETY;
EPISTAXIS;
FATIGUE;
FEBRILE NEUTROPENIA;
FOOD AND DRUG ADMINISTRATION;
GENERAL CONDITION DETERIORATION;
HUMAN;
HYPERTENSION;
HYPONATREMIA;
LEUKODYSTROPHY;
LEUKOPENIA;
LUNG EMBOLISM;
MONOTHERAPY;
NEUTROPENIA;
OVERALL SURVIVAL;
PAIN;
PERIPHERAL NEUROPATHY;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
STOMACH CANCER;
STOMATITIS;
TREATMENT RESPONSE;
VOMITING;
ADENOCARCINOMA;
ADOLESCENT;
ADULT;
ADVERSE DRUG REACTION;
AGED;
CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE FREE SURVIVAL;
ESOPHAGEAL NEOPLASMS;
FEMALE;
KAPLAN MEIER METHOD;
MALE;
MIDDLE AGED;
PATHOLOGY;
RANDOMIZED CONTROLLED TRIAL;
STOMACH NEOPLASMS;
ADENOCARCINOMA;
ADOLESCENT;
ADULT;
AGED;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
DISEASE-FREE SURVIVAL;
DRUG APPROVAL;
DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS;
ESOPHAGEAL NEOPLASMS;
FEMALE;
HUMANS;
KAPLAN-MEIER ESTIMATE;
MALE;
MIDDLE AGED;
PACLITAXEL;
STOMACH NEOPLASMS;
|
EID: 84942879447
PISSN: 10780432
EISSN: 15573265
Source Type: Journal
DOI: 10.1158/1078-0432.CCR-15-0600 Document Type: Article |
Times cited : (76)
|
References (9)
|